Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene

Korábbi kezelés

• Ocular surgery, intravitreal or subretinal implantation of a medical device (within 6 months of screening)
• Any other retinopathy due to other diseases - including, but not limited to arterial hypertension, previous vascular retinal occlusion, trauma or acquired inflammatory diseases, contraindication to pharmacological mydriasis (e.g., history of angle block glaucoma), diabetes (diabetic retinopathy including macular oedema)
• Individuals performing any other therapy for RP within 3 months before the study, such as - but not limited to - transcorneal electrostimulation
• Current, or recent, participation in other study/ or administration of investigational biologic agent within 3 months of Screening; Use of any investigational agent, or systemic corticosteroids, or other immunosuppressive drug(s) within 3 months before Screening
• Previous receipt of any AAV gene therapy product

Más betegség

• Additional interfering ocular conditions which would impact study results (e.g., ocular opacity and advanced cataract, uveitis, amblyopia)
• Mutations known to cause inherited retinal disease other than biallelic variants in the CNGA1 gene
• History of ocular infection with herpes simplex virus
• History of ocular malignancies
• History of disorders of the internal retina (e.g., retinal detachment)
• Systemic conditions (e.g., autoimmune disorders) which may affect study participation or outcome measures
• History of immunodeficiency or other medical conditions which may increase the risk of VG901 administration
• History of allergy or sensitivity to any compound used in the study
• Any condition which leads the investigator to believe that subject cannot comply with the protocol requirements or that may place the subject at an unacceptable risk from participating

Laborértékek

• Patients with uncontrolled diabetes (HbA1c > 7%)
• Systemic illness (e.g., hepatitis or human immunodeficiency virus [HIV] infection) or medically relevant abnormal laboratory values (3 x upper limit of normal [ULN]) in blood analysis including renal and hepatic function
• Subjects with increased risk of bleeding (i.e., use of anticoagulants or anti-platelet agents within 7 days before VG901 administration and subjects with international normalized ratio > 2 or Quick < 50% or partial thromboplastin time > 50 seconds, thrombocytopenia, as well as any other known coagulopathy)

Egyéb

• Subjects will be excluded from the study if one or more of the following statements are applicable to either eye:
• History or presence of glaucoma
• Absence of visual function on the contralateral eye
• Any damage to the optic nerve
• Contraindications to systemic immunosuppression
• Subject/partner of childbearing potential unwilling to use adequate contraception for the period between Screening and 30 days after treatment, defined as the period from Screening until 30 days after treatment (defined as administration of therapeutic to the eye)
• For females of childbearing potential, a positive pregnancy test at Screening or Baseline
• Females who are breastfeeding

• To be eligible for study entry, subjects must satisfy all the following criteria:
• Able to understand and willing to consent to study participation by a written informed consent
• Male or female ≥ 18 years of age
• Clinical diagnosis of RP
• Confirmed pathogenic, biallelic variants in the CNGA1 gene
• Ellipsoid zone (EZ) length of the fovea of ≥ 3000 μm in the study eye